(Total Views: 450)
Posted On: 12/18/2017 12:33:49 PM
Post# of 30035
In other news
Novartis AG will pay $130 million to acquire a Priority Review Voucher from Ultragenyx Pharmaceutical Inc. in a move likely aimed at accelerating regulatory review for one of several potential blockbuster medicines the Swiss pharma plans to file for approval sometime in 2018.
https://www.biopharmadive.com/news/novartis-u...on/513303/
Novartis AG will pay $130 million to acquire a Priority Review Voucher from Ultragenyx Pharmaceutical Inc. in a move likely aimed at accelerating regulatory review for one of several potential blockbuster medicines the Swiss pharma plans to file for approval sometime in 2018.
https://www.biopharmadive.com/news/novartis-u...on/513303/
(5)
(0)Scroll down for more posts ▼
